Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.548
-0.002 (-0.44%)
Mar 4, 2025, 10:57 AM EST - Market open
MTNB Revenue
In the year 2023, Matinas BioPharma Holdings had annual revenue of $1.10M, down -65.62%.
Revenue (ttm)
$1.10M
Revenue Growth
-65.62%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
2.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.10M | -2.09M | -65.62% |
| Dec 31, 2022 | 3.19M | 3.16M | 9,560.61% |
| Dec 31, 2021 | 33.00K | -125.33K | -79.16% |
| Dec 31, 2020 | 158.33K | 68.52K | 76.29% |
| Dec 31, 2019 | 89.81K | -29.94K | -25.00% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
MTNB News
- 18 days ago - Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors - GlobeNewsWire
- 25 days ago - Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair - GlobeNewsWire
- 7 weeks ago - Matinas BioPharma Receives NYSE Noncompliance Notice - GlobeNewsWire
- 4 months ago - Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction - GlobeNewsWire
- 7 months ago - Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 7 months ago - Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024 - GlobeNewsWire
- 9 months ago - Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program - GlobeNewsWire